financetom
Business
financetom
/
Business
/
JD.com Prices Upsized $1.75 Billion Convertible Senior Notes Offering, Plans to Repurchase 14 Million ADSs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JD.com Prices Upsized $1.75 Billion Convertible Senior Notes Offering, Plans to Repurchase 14 Million ADSs
May 21, 2024 7:32 AM

10:13 AM EDT, 05/21/2024 (MT Newswires) -- JD.com ( JD ) said Tuesday it has priced an offering of $1.75 billion of its convertible senior notes to qualified institutional buyers.

The offering, which was upsized from the initial $1.5 billion, is set to close around Thursday.

The initial conversion rate of the notes is 21.8830 American depositary shares per $1,000 principal amount of the notes, which is equivalent to an initial conversion price of about $45.70 per ADS. Each ADS represents two class A ordinary shares.

Initial purchasers have been granted an option to buy up to an additional $250 million in principal amount of the notes.

Meanwhile, the company also said it plans to repurchase about 14 million ADSs from certain note purchasers through a concurrent repurchase plan.

Net proceeds from the notes offering are to be used to fund the repurchase plan, to fund overseas business, to support the company's supply chain network, and for working capital needs, the company said.

Shares of JD.com ( JD ) were down more than 3% in recent Tuesday trading.

Price: 33.44, Change: -1.31, Percent Change: -3.77

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
May 15, 2024
04:24 AM EDT, 05/15/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Arcutis Biotherapeutics' ( ARQT ) shares surged more than 20% in premarket activity on Wednesday after the company reported a narrower loss and handily beat market expectations for sales. The company reported a Q1 loss late Tuesday of $0.32 per diluted...
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
May 15, 2024
04:32 AM EDT, 05/15/2024 (MT Newswires) -- Novonix ( NVX ) said late Tuesday it signed a non-exclusive testing and development agreement with Volkswagen-owned PowerCo to come up with synthetic graphite anode materials for electric vehicle batteries. The companies could later enter into a supply agreement for the products developed under the deal, Novonix ( NVX ) said. Financial terms...
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
May 15, 2024
04:26 AM EDT, 05/15/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday that the latter has initiated a rolling submission of a biologics license application to the US Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector as a weekly maintenance treatment for early Alzheimer's disease. The application came after the treatment, commercially known as Leqembi, was granted FDA fast-track...
Thyssenkrupp cuts sales, profit forecasts amid gloomy market
Thyssenkrupp cuts sales, profit forecasts amid gloomy market
May 15, 2024
* Now expects net loss vs break even in 2023/24 * Books impairments on materials trading division * Thyssenkrupp shares -5.7%, Thyssenkrupp Nucera -8% (Adds details on tariff discussion in paragraph) By Christoph Steitz and Tom Käckenhoff FRANKFURT, May 15 (Reuters) - German conglomerate Thyssenkrupp cut its annual forecasts for sales and net profit for the second time in three...
Copyright 2023-2025 - www.financetom.com All Rights Reserved